Press Room

Share

CMS Rejects Proposed Change to ‘Six Protected Classes’ Medicare Drug Coverage

Change Could Have Risked Cancer Patients’ Timely Access to Prescription Drugs

March 17, 2021

Washington, D.C.—The Centers for Medicare and Medicaid Services (CMS) announced this week that it will not proceed with additional flexibilities to a Part D Payment Modernization Model that would have allowed participating Medicare Part D plans to limit coverage of drugs within the “six protected drug classes.” The additional flexibilities—proposed under the prior administration—would have allowed plans to treat drugs within the six protected classes as any other Part D drugs; meaning Part D plans could choose to no longer cover or substantially restrict all drugs within these classes. These changes could have delayed cancer patients’ timely access to therapies.

By halting the change, Medicare Part D plan sponsors participating in the Part D Payment Modernization Model will continue to be required to cover all or substantially all drug therapies in the designated six protected classes, including oncology drugs, once they are approved by the FDA.

A statement from Lisa Lacasse, president of the American Cancer Society Cancer Action Network (ACS CAN) follows:

“We’re thrilled that patient voices and concerns were heard and that this proposed change will not move forward. Ensuring cancer patients have access to the latest, most innovative, and often times the only treatment for their type of cancer, is essential. Delayed access to prescription medicines can have dramatic consequences for cancer patients, which is why the cancer therapies were included among these protected classes to begin with.

“Halting this proposed change was the right thing for patients as this action will preserve critical patient access to innovative treatments.”

 

More Press Releases AboutAccess to Health Care, National

Media Contacts

Allison Miller
Director, Media Advocacy
Washington, D.C.
[email protected]
202-585-3241
Alissa Crispino
Vice President, Media Advocacy & Communications
Washington, D.C.
[email protected]
202-661-5772

Related Press Releases

January 8, 2025

Advocates Set Sights on Improving Access to Cancer Care, Reducing Burden of Disease for Maryland Patients in 2025

The following is a statement from American Cancer Society Cancer Action Network (ACS CAN) Maryland Government Relations Director Lance Kilpatrick:

“In 2024, Maryland state lawmakers heard from advocates across the disease spectrum and from every corner of the state, who united together to send a resounding message: improve access to lifesaving medication. Though the legislature did not advance the proposal to prohibit the use of copay accumulator adjustment programs, advocates are hopeful that lawmakers won’t miss the same opportunity in 2025.

Read More
January 8, 2025

Mother, Daughter Survive Cancer & Send Message to Lawmakers: Reduce the Burden of Cancer in New Jersey

Two years after Ocean City local Jeanmarie Mason’s breast cancer returned and spread to her bones, her daughter Julie Groob also experienced a recurrence of her cervical cancer, bringing the two closer together than ever and uniting them in the fight against cancer. As volunteers with the American Cancer Society Cancer Action Network (ACS CAN), Jeanmarie and Julie were among key voices in securing a medical debt relief victory in 2024. The pair are approaching the legislative session in 2025 eager to share their stories and advance critical proposals to limit the burden of disease across the cancer continuum.

Read more
January 7, 2025

Advocates Set Sights on Improving Access to Cancer Prevention & Detection, Reducing Burden of Disease for PA Patients in 2025

The following is a statement from American Cancer Society Cancer Action Network (ACS CAN) Pennsylvania Government Relations Director Donna Greco:

“In 2024, ACS CAN was proud to see the Pennsylvania Legislature mobilize swiftly and in a bipartisan manner to bring the promise of precision medicine to more patients. Beginning in the new year, Act 39 of 2024 will make it so that all patients who can benefit and are insured through a state-regulated health plan will receive coverage for biomarker testing, a game changer in the fight against cancer and an essential step in accessing precision medicine treatments. Pennsylvanians also secured a victory for access to care through Act 42 of 2024, the newly enacted legislation that includes telemedicine as a covered benefit in the Commonwealth.

Read more